Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Stock Upgrades: Immunome Inc Shows Rising Relative Strength

Immunome Inc had its Relative Strength (RS) Rating upgraded from 71 to 86 Tuesday.

As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.

IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.

Decades of market research reveals that the market's biggest winners often have an RS Rating of over 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Immunome Inc is now considered extended and out of buy range after clearing a 16.87 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.

Immunome Inc posted -64% EPS growth in the latest quarterly report. Sales increased 0%.

The company earns the No. 195 rank among its peers in the Medical-Biomed/Biotech industry group. Biontech Se Ads and Alkermes are also among the group's highest-rated stocks.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.